Objective:To observe clinical effects of Kang'ai injection joined with SOX(Tegafur,gimeracil and oteracil potassium capsules and oxaliplatin)chemotherapy in the treatment of advanced gastric cancer.Methods:One hundred patients with advanced gastric cancer who agreed to chemotherapy were selected,and allocated to the control group and the observation group according to random number table method,with 50 cases in each group.The control group used SOX therapeutic regimen,intravenous injection of oxaliplatin for injection,meanwhile oral administration of Tegafur,gimeracil and oteracil potassium capsules.The observation group accepted intravenous injection of Kang'ai injection,both groups were treated for 14 days consecutively,seven days'break,21 days were one course of the treatment,for three therapeutic cycles continuously.To observe clinical total effective rate,disease control rate,the levels of serum tumor markers,KPS scores and the incidence of adverse reaction of the two groups.Results:After three therapeutic cycles,total effective rate of the observation group was[64.0%(32/50)],better than[48.0%(24/50)]of the control group(P＜0.05);disease control rate of the observation group was[84.0%(42/50)],higher than[70.0%(35/50)]of the control group(P＜0.05).After the treatment,the levels of CEA,CA199 and CA724 of the observation group were lower than these of the control group,KPS scores higher than these of the control group(P＜0.05);the incidence of adverse reaction of the observation group was[28.0%(14/50)],lower than[42.0%(21/50)]of the control group(P＜0.05).Conclusion:Kang'ai injection combined with SOX chemotherapy could lower the levels of tumor markers,raise the patients'quality of life and reduce the incidence of adverse reaction in the treatment of advanced gastric cancer.
gastric cancer,advancedKang'ai injectionTegafur,gimeracil and oteracil potassium capsulesoxaliplatinchemotherapyclinical study
维普
万方数据
